Got a bit ahead of itself and came off in November. Has gone through some difficult years and has had some management changes. Likes the new CEO. They are looking at getting into China and leveraging up on the olympics.
They have an isotope that is a less invasive way of treating prostrate cancer as opposed to surgery. They're dominant in this field. Had difficulty because of insurance coverage issues. Their competition also has treatment methods, so have competition. Losing money because of more going into R & D. New marketing may help.
Has had a bumpy ride. Still really struggling. Still losing money. No debt and lots of cash. Have to work on their business model. Expect it will be sitting in their portfolio for quite some time.
Consultants software programming helping companies' outsourcing. Got hit by the collapse of the tech bubble and outsourcing to places like India. Now appears to have turned the corner. Have made money the last 3 quarters. Made an acquisition that will give them some presence in the voice over IP. Good relationship with Cisco.
Need a scorecard to keep track of who is taking over who. Doesn't know how it's going to end up. If he owned, would hang on to see where the dust settles.
Treat as a HOLD, not as a BUY. Takeover scuttlebut seems to have dried up. Likes the company and their assets and wouldn't count the aspect of a takeover as being finished. Pays a very nice dividend. Suffered the last few years because of WalMart and feels that WalMart may be topping out in Canada. Making some good changes.